Hypoxic pulmonary vasoconstriction

Physiological response of the pulmonary circulation to low alveolar oxygen

Hypoxic pulmonary vasoconstriction
Pulmonary circulation.svg
Synonyms	HPV; hypoxic pulmonary vasoconstrictive response; hypoxic pulmonary arterial vasoconstriction; alveolar hypoxia-induced pulmonary vasoconstriction; Euler-Liljestrand mechanism
Pronounce	N/A
Specialty	N/A
Symptoms	Usually none when localized and physiologic; diffuse or exaggerated HPV may contribute to dyspnea, hypoxemia, reduced exercise tolerance, chest discomfort, or signs of pulmonary hypertension
Complications	Ventilation-perfusion mismatch, worsening hypoxemia, increased pulmonary vascular resistance, pulmonary hypertension, right ventricular hypertrophy, cor pulmonale, high-altitude pulmonary edema, perioperative hypoxemia during one-lung ventilation
Onset	Seconds to minutes after a fall in regional alveolar oxygen tension
Duration	Reversible within minutes to hours if oxygenation improves; sustained hypoxia over days to months may contribute to pulmonary vascular remodeling
Types	N/A
Causes	Low alveolar oxygen tension, regional hypoventilation, airway obstruction, atelectasis, high altitude, lung disease, one-lung ventilation, or diffuse chronic hypoxemia
Risks	Chronic obstructive pulmonary disease, interstitial lung disease, sleep apnea, obesity hypoventilation syndrome, high-altitude exposure, congenital heart or lung disease, pulmonary vascular disease, acute lung injury, anesthesia with one-lung ventilation
Diagnosis	Not usually diagnosed as a separate disease; inferred from clinical physiology, gas exchange, imaging, pulmonary hemodynamics, oxygen response, and research measurements of pulmonary vascular tone
Differential diagnosis	Pulmonary embolism, pulmonary hypertension, acute respiratory distress syndrome, atelectasis, pneumonia, asthma, COPD exacerbation, heart failure, right-to-left shunt, high-altitude pulmonary edema
Prevention	Prevent harmful diffuse or exaggerated HPV by correcting hypoxemia, avoiding rapid ascent to high altitude, treating lung disease, preventing atelectasis, optimizing ventilation, and using supplemental oxygen when clinically indicated
Treatment	Physiologic HPV requires no treatment; maladaptive HPV is managed by correcting hypoxia, treating the underlying lung or altitude-related disorder, optimizing ventilation, and using pulmonary vasodilator therapy only in selected clinical settings
Medication	Oxygen therapy when indicated; bronchodilators, corticosteroids, antibiotics, diuretics, or disease-specific therapy depending on cause; nifedipine, phosphodiesterase-5 inhibitors, or other pulmonary vasodilators in selected high-altitude or pulmonary hypertension contexts under medical supervision
Prognosis	Beneficial when localized and reversible; prognosis depends on the underlying cause when HPV is diffuse, chronic, or exaggerated
Frequency	Universal physiologic response in humans and many mammals; clinically important in lung disease, high-altitude exposure, and anesthesia
Deaths	N/A

Hypoxic pulmonary vasoconstriction (HPV) is a physiological response in which small pulmonary arteries and arterioles constrict when the surrounding alveoli have low oxygen tension. Unlike most systemic arteries, which usually dilate in response to local hypoxia, the pulmonary circulation constricts in poorly ventilated lung regions. This helps redirect blood away from low-oxygen alveoli toward better-ventilated alveoli, improving ventilation-perfusion matching and supporting arterial oxygenation.

HPV is also called the Euler-Liljestrand mechanism. It is one of the key differences between the systemic circulation and the pulmonary circulation. In the systemic circulation, local hypoxia generally increases blood flow to oxygen-starved tissues. In the lung, local alveolar hypoxia reduces blood flow to poorly ventilated alveoli so that perfusion is directed toward regions that can better oxygenate blood.

HPV is normally protective when it is localized and temporary. However, when hypoxia is diffuse, prolonged, or excessive, HPV can increase pulmonary vascular resistance, raise pulmonary artery pressure, and contribute to pulmonary hypertension, right ventricular strain, and cor pulmonale. This is clinically important in disorders such as chronic obstructive pulmonary disease, interstitial lung disease, sleep apnea, high-altitude pulmonary edema, and during one-lung ventilation in anesthesia.

Definition

Hypoxic pulmonary vasoconstriction is the constriction of the pulmonary vasculature in response to reduced partial pressure of oxygen in the alveoli. The response occurs mainly in small muscular pulmonary arteries and arterioles near poorly ventilated alveoli.

HPV should be understood as a physiologic reflex rather than a disease. It becomes clinically significant when it is:

• Excessive
• Diffuse throughout both lungs
• Persistent
• Associated with chronic hypoxemia
• Associated with pulmonary vascular remodeling
• Present in a patient with limited cardiopulmonary reserve

Purpose

The main purpose of HPV is to improve gas exchange by matching blood flow to ventilation. When a region of the lung receives little oxygen because of poor ventilation, continued perfusion of that region would create a functional shunt and lower arterial oxygen levels. HPV limits this effect by reducing blood flow to the hypoxic region.

The response helps:

• Reduce perfusion of poorly ventilated alveoli
• Improve ventilation-perfusion matching
• Preserve arterial oxygenation
• Limit intrapulmonary shunting
• Support efficient pulmonary gas exchange

Normal physiology

In a healthy lung, ventilation and perfusion are not perfectly uniform. Gravity, posture, airway caliber, regional lung mechanics, and vascular tone all affect the distribution of air and blood. HPV provides a local feedback mechanism that adjusts pulmonary blood flow according to regional alveolar oxygen levels.

When a small area of the lung becomes poorly ventilated, such as during mucus plugging or mild atelectasis, HPV can redirect blood toward better-ventilated alveoli. This is beneficial because it helps preserve systemic oxygen delivery.

Contrast with systemic circulation

Feature	Systemic circulation	Pulmonary circulation
Response to local hypoxia	Usually vasodilation	Vasoconstriction
Main purpose	Increase blood flow to hypoxic tissue	Reduce blood flow to poorly ventilated alveoli
Effect on gas exchange	Delivers more oxygen to tissue	Improves ventilation-perfusion matching
Clinical consequence if diffuse	May lower systemic vascular resistance	May raise pulmonary vascular resistance and pulmonary artery pressure

Mechanism

HPV is initiated when alveolar oxygen tension falls. The sensor-effector system is located primarily in the pulmonary arterial smooth muscle and associated endothelial and mitochondrial signaling pathways.

The exact mechanism is complex and remains an active area of research, but major components include:

• Inhibition of oxygen-sensitive potassium channels
• Membrane depolarization of pulmonary arterial smooth muscle cells
• Opening of voltage-gated calcium channels
• Increased intracellular calcium
• Smooth muscle contraction
• Modulation by the pulmonary endothelium
• Effects of nitric oxide, endothelin, prostacyclin, thromboxane, and reactive oxygen species
• Mitochondrial oxygen sensing and redox signaling

Oxygen sensing

Pulmonary vascular smooth muscle cells respond to reduced oxygen tension by changing ion-channel activity and intracellular signaling. Oxygen-sensitive potassium channels are believed to play an important role. When these channels are inhibited, the cell membrane depolarizes, calcium entry increases, and vascular smooth muscle contracts.

Calcium signaling

Increased intracellular calcium is a final common pathway for pulmonary vasoconstriction. Calcium enters through voltage-gated channels and may also be released from intracellular stores. The rise in cytosolic calcium promotes actin-myosin interaction and vascular smooth muscle contraction.

Endothelial modulation

The endothelium influences the strength of HPV. Endothelial-derived mediators can either enhance or reduce pulmonary vasoconstriction.

Important mediators include:

• Nitric oxide - generally vasodilatory
• Prostacyclin - vasodilatory and antiplatelet
• Endothelin - vasoconstrictive
• Thromboxane - vasoconstrictive
• Reactive oxygen species - context-dependent signaling effects

Biphasic response

HPV may occur in phases. An early response develops within seconds to minutes after alveolar oxygen tension falls. A later sustained phase may develop if hypoxia persists. Chronic hypoxia can lead to structural changes in the pulmonary vasculature, including muscularization and remodeling of small arteries.

Triggers

Common triggers of HPV include:

• Regional alveolar hypoxia
• Airway obstruction
• Atelectasis
• Pneumonia
• Asthma exacerbation
• COPD exacerbation
• Interstitial lung disease
• Pulmonary edema
• Sleep apnea
• Obesity hypoventilation syndrome
• High-altitude exposure
• One-lung ventilation during thoracic surgery
• Hypoventilation from sedatives or anesthesia
• Congenital or acquired right-to-left shunt physiology

Factors that influence HPV

The magnitude of HPV varies depending on oxygen tension, carbon dioxide tension, pH, temperature, drugs, vascular health, and the presence of lung disease.

Factors that may increase HPV

• Lower alveolar oxygen tension
• Hypercapnia
• Acidosis
• High altitude
• Sympathetic activation
• Pulmonary vascular disease
• Chronic hypoxemia
• Some inflammatory states

Factors that may decrease HPV

• Supplemental oxygen
• Improved ventilation
• Alkalosis
• Hypocapnia in some settings
• Pulmonary vasodilators
• Some inhaled or intravenous anesthetic agents
• Sepsis or systemic inflammation
• Excessive vasodilation

Clinical significance

Beneficial localized HPV

Localized HPV is useful when only part of the lung is poorly ventilated. Examples include mucus plugging, focal atelectasis, or regional pneumonia. By reducing perfusion to the affected region, HPV reduces shunting and helps maintain oxygenation.

Maladaptive diffuse HPV

When hypoxia affects large portions of the lung or the entire lung, HPV becomes less helpful. Instead of redirecting blood to better-ventilated areas, it raises resistance throughout the pulmonary circulation. This can increase the workload of the right ventricle.

Diffuse or chronic HPV may contribute to:

• Pulmonary hypertension
• Right ventricular hypertrophy
• Cor pulmonale
• Reduced exercise capacity
• Worsening hypoxemia
• Pulmonary vascular remodeling

HPV in chronic lung disease

In chronic lung diseases, especially chronic obstructive pulmonary disease, persistent hypoxemia can produce chronic pulmonary vasoconstriction and structural remodeling of pulmonary vessels. In COPD, pulmonary hypertension may reflect several mechanisms, including hypoxic vasoconstriction, loss of vascular bed from emphysema, hyperinflation, inflammation, endothelial dysfunction, and polycythemia.

Clinical settings where HPV may contribute to disease include:

• Chronic obstructive pulmonary disease
• Emphysema
• Chronic bronchitis
• Interstitial lung disease
• Cystic fibrosis
• Bronchiectasis
• Sleep-disordered breathing
• Obesity hypoventilation syndrome

HPV and high altitude

At high altitude, lower barometric pressure reduces inspired and alveolar oxygen tension. This can cause widespread pulmonary vasoconstriction. In susceptible individuals, exaggerated and uneven HPV can raise pulmonary artery pressure and contribute to high-altitude pulmonary edema.

High-altitude pulmonary edema is associated with:

• Rapid ascent
• Inadequate acclimatization
• Exaggerated pulmonary vasoconstriction
• Increased pulmonary artery pressure
• Patchy overperfusion of less constricted vessels
• Capillary stress failure and leakage
• Severe hypoxemia

Prevention and treatment of high-altitude illness may include slower ascent, descent, oxygen, rest, and selected medications under medical guidance.

HPV in anesthesia and surgery

HPV is important during thoracic surgery and one-lung ventilation. During one-lung ventilation, the nonventilated lung may continue to receive blood flow, creating a shunt. HPV reduces blood flow to the nonventilated lung and helps limit the fall in arterial oxygenation.

Anesthetic management may affect HPV. Some anesthetic agents, vasodilators, high airway pressures, hypothermia, alkalosis, and excessive pulmonary vasodilation can reduce HPV and worsen oxygenation. Anesthesiologists manage this by optimizing ventilation, oxygenation, lung recruitment, airway pressures, positioning, and hemodynamics.

HPV and oxygen therapy

Supplemental oxygen can reverse hypoxic pulmonary vasoconstriction by increasing alveolar oxygen tension. In many conditions, this is beneficial because it lowers pulmonary vascular resistance and improves oxygenation.

However, in some patients with COPD and chronic hypercapnia, excessive oxygen administration can worsen carbon dioxide retention through several mechanisms, including worsened ventilation-perfusion mismatch, reduced hypoxic vasoconstriction in poorly ventilated regions, the Haldane effect, and changes in minute ventilation.

Diagnosis

HPV is not usually diagnosed as a standalone disease. It is a physiological mechanism inferred from clinical context and cardiopulmonary testing.

Evaluation may include:

• Pulse oximetry
• Arterial blood gas
• Chest imaging
• Pulmonary function testing
• Echocardiography
• Computed tomography pulmonary angiography when pulmonary embolism is suspected
• Ventilation-perfusion scan
• Right heart catheterization when pulmonary hypertension must be confirmed
• Sleep testing when sleep apnea is suspected
• High-altitude exposure history

Differential diagnosis

Clinical problems that may mimic or coexist with harmful HPV include:

• Pulmonary embolism
• Pulmonary arterial hypertension
• Pulmonary venous hypertension
• Left heart failure
• Acute respiratory distress syndrome
• Pneumonia
• Atelectasis
• Asthma
• COPD exacerbation
• Interstitial lung disease
• High-altitude pulmonary edema
• Right-to-left shunt
• Congenital heart disease
• Obesity hypoventilation syndrome

Management

Physiologic HPV does not require treatment. Management is directed at harmful hypoxemia, pulmonary hypertension, high-altitude illness, or the underlying lung disease.

General management principles

• Correct low alveolar oxygen when clinically appropriate
• Treat airway obstruction
• Treat infection or inflammation
• Reverse atelectasis when possible
• Optimize ventilation and perfusion
• Avoid unnecessary pulmonary vasodilators when they may worsen shunt
• Evaluate for pulmonary hypertension if symptoms or signs suggest it
• Treat sleep apnea or nocturnal hypoxemia
• Use long-term oxygen therapy when indicated for chronic severe hypoxemia

Management in chronic lung disease

Treatment depends on the underlying cause and may include:

• Smoking cessation
• Bronchodilator therapy
• Pulmonary rehabilitation
• Vaccination against respiratory infections
• Oxygen therapy when indicated
• Treatment of sleep-disordered breathing
• Management of exacerbations
• Evaluation for pulmonary hypertension

Management at high altitude

For altitude-related exaggerated HPV or high-altitude pulmonary edema, management may include:

• Immediate descent
• Supplemental oxygen
• Rest and warming
• Portable hyperbaric chamber if descent is not possible
• Nifedipine in selected cases
• Phosphodiesterase-5 inhibitors in selected prevention or treatment settings
• Avoidance of further ascent until symptoms resolve

Management during anesthesia

During one-lung ventilation or thoracic surgery, clinicians may use:

• High inspired oxygen concentration when appropriate
• Confirmation of lung isolation device position
• Recruitment of ventilated lung
• Optimization of positive end-expiratory pressure
• Continuous positive airway pressure to the nonventilated lung in selected cases
• Avoidance of excessive pulmonary vasodilation
• Hemodynamic optimization
• Conversion to two-lung ventilation if needed

Medications that may affect HPV

Drug or drug class	Possible relevance to HPV
Oxygen	Reverses hypoxia-driven pulmonary vasoconstriction by improving alveolar oxygen tension
Inhaled nitric oxide	Selective pulmonary vasodilator that may improve oxygenation in selected intensive-care settings by dilating vessels in ventilated lung regions
Prostacyclin analogs	Pulmonary vasodilators used in selected pulmonary hypertension settings; may worsen V/Q mismatch if nonselective
Phosphodiesterase-5 inhibitors	May reduce pulmonary vascular tone; used in selected pulmonary hypertension and high-altitude contexts
Nifedipine	May reduce high-altitude pulmonary pressure in susceptible individuals under medical supervision
Volatile anesthetics	May inhibit HPV to varying degrees, especially at higher doses
Intravenous anesthetics	Variable effects; generally considered in perioperative oxygenation planning
Bronchodilators	Improve ventilation in obstructive lung disease and may indirectly reduce regional hypoxia

Prognosis

Localized and reversible HPV is beneficial and has no adverse prognosis by itself. Prognosis depends on the cause when HPV is diffuse or chronic.

Poorer prognosis may occur when HPV is associated with:

• Advanced COPD
• Severe interstitial lung disease
• Chronic hypoxemia
• Pulmonary hypertension
• Right ventricular dysfunction
• Recurrent high-altitude pulmonary edema
• Acute respiratory failure

Research

Research on HPV focuses on oxygen sensing, mitochondrial signaling, ion channels, endothelial mediators, redox biology, and therapeutic modulation of pulmonary vascular tone. A major challenge is that HPV is beneficial in localized lung disease but harmful when diffuse or chronic. Therefore, therapies must be targeted carefully so that they reduce harmful pulmonary hypertension without worsening ventilation-perfusion mismatch.

Potential research areas include:

• Oxygen-sensitive potassium channels
• Mitochondrial redox signaling
• Calcium sensitization pathways
• Endothelin signaling
• Nitric oxide biology
• Pulmonary vascular remodeling
• Selective pulmonary vasodilator delivery
• High-altitude susceptibility
• HPV during anesthesia and critical care

Key points

• HPV is a normal pulmonary vascular response to low alveolar oxygen.
• The response helps match perfusion to ventilation.
• Localized HPV is usually beneficial.
• Diffuse or chronic HPV may contribute to pulmonary hypertension.
• HPV is clinically important in COPD, interstitial lung disease, high altitude, sleep apnea, anesthesia, and critical care.
• Treatment is directed at the underlying cause rather than HPV itself.

See also

• Pulmonary circulation
• Pulmonary hypertension
• Gas exchange
• Ventilation-perfusion ratio
• Alveolar ventilation
• Hypoxia
• Hypoxemia
• Chronic obstructive pulmonary disease
• High-altitude pulmonary edema
• Cor pulmonale
• Right ventricle
• One-lung ventilation
• Anesthesiology
• Respiratory physiology

External links

• Physiology, Pulmonary Vasoconstriction - NCBI Bookshelf
• Hypoxic pulmonary vasoconstriction: From physiology to clinical implications
• Altitude illness - Merck Manual Professional Edition